Anesthetic Management of Myasthenia Gravis

Introduction to Anesthetic Considerations

• Patients with myasthenia gravis require a 50-75% dose reduction of non-depolarizing neuromuscular blocking agents due to increased sensitivity, and sugammadex is the preferred reversal agent 1, 2

Neuromuscular Blocking Agents

• Increased sensitivity and prolonged duration of action of non-depolarizing NMBAs occur because antibodies reduce functional acetylcholine receptors at the neuromuscular junction 1, 2
• The initial dose of atracurium and cisatracurium should be reduced by 50-75% 1, 2
• The degree of sensitivity to non-depolarizing NMBAs correlates directly with disease severity 1, 2
• Benzylisoquinoline agents, such as atracurium and cisatracurium, are preferred due to their organ-independent elimination via Hofmann degradation, making them more predictable 1, 2
• Resistance to succinylcholine occurs, requiring increased doses to achieve the same effect, due to receptor down-regulation 1

Reversal of Neuromuscular Blockade

• Sugammadex is strongly recommended over neostigmine for reversal of rocuronium or vecuronium in myasthenia gravis patients 1, 2
• Neostigmine may interfere with long-term anticholinesterase treatment and is less predictable 1
• The risks of residual neuromuscular blockade are significantly increased in myasthenia gravis 1

Preoperative Assessment and Optimization

• Measure negative inspiratory force and vital capacity in all patients preoperatively 3, 4
• Apply the "20/30/40 rule" to identify high-risk patients: VC <20 mL/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 3, 4
• Patients with moderate to severe generalized weakness require frequent pulmonary function assessments 3, 4
• Respiratory insufficiency may develop without obvious dyspnea symptoms 3, 4
• Continue pyridostigmine on the day of surgery, as discontinuation increases the risk of respiratory distress 2
• 30 mg oral pyridostigmine corresponds to 1 mg IV or 0.75 mg neostigmine IM 3

Intraoperative Management

• Volatile anesthetics potentiate neuromuscular blockade and may allow avoidance of NMBAs entirely 1
• Regional anesthesia is preferred when feasible to avoid NMBAs 1
• Factors that potentiate neuromuscular blockade include inhalation anesthetics, antibiotics, magnesium salts, lithium, local anesthetics, procainamide, and quinidine 1

Postoperative Management

• Monitor for signs of myasthenic crisis requiring immediate intervention 3, 4
• For intubated patients, discontinue or withhold pyridostigmine 3
• Higher-risk patients include those with severe generalized disease, baseline respiratory compromise, and prolonged surgical procedures 3, 4

Key Considerations

• Never use standard NMBA doses - always reduce by 50-75% 1, 2
• Never administer IV magnesium - it is absolutely contraindicated 3
• Never discontinue anticholinesterase therapy preoperatively without careful consideration 2
• Never assume normal respiratory function based on lack of dyspnea - objective testing is mandatory 3, 4

Anesthetic Management in Myasthenia Gravis

Respiratory Monitoring and Support

• The American Thoracic Society recommends monitoring SpO₂ continuously and, whenever possible, blood or end-tidal carbon dioxide levels in patients with myasthenia gravis requiring sedation 5
• Noninvasive positive-pressure ventilation should be considered for ventilatory support in patients with myasthenia gravis, as it has been successful even in patients with bulbar weakness 5

Special Anesthetic Considerations

• The American Academy of Ophthalmology recommends particular care in the use of anesthetic agents for strabismus surgery in myasthenia gravis patients, given any evidence of associated weakness of respiratory muscles 6
• Surgical management should only be considered after remission or stabilization of the disease, often after 2-3 years of treatment, according to the American Academy of Ophthalmology 6

Fentanyl Use in Myasthenia Gravis

Introduction to Fentanyl Safety

• Fentanyl can be safely used in patients with myasthenia gravis and is actually preferred over other opioids, as it does not interact with monoamine oxidase inhibitors and provides predictable analgesia without directly affecting neuromuscular transmission 7

Key Safety Considerations

• Fentanyl is a synthetic opioid that acts on central opioid receptors and does not directly interfere with acetylcholine receptors or neuromuscular junction function 7, 8
• Unlike meperidine, fentanyl has not been implicated in serious drug interactions with monoamine oxidase inhibitors 7
• Standard fentanyl dosing can typically be used: initial dose 50-100 µg IV, with supplemental doses of 25 µg every 2-5 minutes until adequate sedation is achieved 7, 8
• Onset of action is 1-2 minutes with duration of effect 30-60 minutes 7, 8
• A 50% or greater dose reduction is indicated in elderly patients 7

Critical Respiratory Monitoring

• The primary concern with fentanyl in myasthenia gravis is respiratory depression, which may persist longer than the analgesic effect 7, 8
• Respiratory depression is the major adverse effect and requires continuous monitoring 7, 8

Synergistic Effects to Avoid

• The concomitant use of benzodiazepines with opioids has a synergistic effect on respiratory depression risk 7, 8
• If combining fentanyl with midazolam or diazepam, use extreme caution and be prepared to provide respiratory support 7, 9
• There is an increased incidence of apnea when fentanyl is combined with other sedative agents 9
• Factors that worsen neuromuscular transmission include inhalation anesthetics, certain antibiotics (fluoroquinolones, aminoglycosides, macrolides), magnesium salts, lithium, local anesthetics, procainamide, and quinidine 10

Reversal Agent Availability

• Naloxone should be immediately available to reverse life-threatening respiratory depression: 0.1 mg/kg IV (or 0.2-0.4 mg in adults) every 2-3 minutes until desired response 7, 9
• Onset of action is 1-2 minutes, but half-life is only 30-45 minutes, requiring extended monitoring (up to 2 hours) for potential resedation 7, 9
• Use lower doses (1-15 µg/kg) to reverse respiratory depression associated with therapeutic opioid use to avoid complete reversal of analgesia 9

Advantages Over Other Opioids

• Fentanyl has relatively little effect on the cardiovascular system compared to meperidine 7
• Unlike meperidine, fentanyl can be safely used in patients with renal insufficiency without risk of neurotoxic metabolite accumulation 8

Critical Contraindications to Remember

• Never administer IV magnesium to myasthenia gravis patients—it is absolutely contraindicated as it potentiates neuromuscular blockade and can precipitate respiratory failure 10
• Immediately discontinue beta-blockers, fluoroquinolones, aminoglycosides, and macrolide antibiotics if the patient is taking them 10
• For intubated patients in myasthenic crisis, discontinue or withhold pyridostigmine 10